Flunitazene
Appearance
![]() | |
Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
UNII | |
Chemical and physical data | |
Formula | C20H23FN4O2 |
Molar mass | 370.428 g·mol−1 |
3D model (JSmol) | |
| |
|
Flunitazene (Fluonitazene) is a benzimidazole derivative with opioid effects, first developed in the 1950s as part of the research that led to better-known compounds such as etonitazene. It is one of the least potent derivatives from this class to have appeared as a designer drug, with only around the same potency as morphine, but nevertheless has been sold since around 2020, and has been linked to numerous drug overdose cases.[1][2][3][4][5][6]
See also
References
- ^ Lamy FR, Daniulaityte R, Barratt MJ, Lokala U, Sheth A, Carlson RG (August 2021). ""Etazene, safer than heroin and fentanyl": Non-fentanyl novel synthetic opioid listings on one darknet market". Drug and Alcohol Dependence. 225: 108790. doi:10.1016/j.drugalcdep.2021.108790. PMID 34091156. S2CID 235362241.
- ^ "A review of the evidence on the use and harms of 2-benzyl benzimidazole ('nitazene') and piperidine benzimidazolone ('brorphine-like') opioids" (PDF). UK: Advisory Council on the Misuse of Drugs. July 2022.
- ^ Walton SE, Krotulski AJ, Logan BK (March 2022). "A Forward-Thinking Approach to Addressing the New Synthetic Opioid 2-Benzylbenzimidazole Nitazene Analogs by Liquid Chromatography-Tandem Quadrupole Mass Spectrometry (LC-QQQ-MS)". Journal of Analytical Toxicology. 46 (3): 221–231. doi:10.1093/jat/bkab117. PMC 8935987. PMID 34792157.
- ^ Montanari E, Madeo G, Pichini S, Busardò FP, Carlier J (August 2022). "Acute Intoxications and Fatalities Associated With Benzimidazole Opioid (Nitazene Analog) Use: A Systematic Review". Therapeutic Drug Monitoring. 44 (4): 494–510. doi:10.1097/FTD.0000000000000970. PMID 35149665. S2CID 246776288.
- ^ Schüller M, Lucic I, Leere Øiestad ÅM, Pedersen-Bjergaard S, Øiestad EL (September 2023). "High-throughput quantification of emerging nitazene benzimidazole opioid analogs by microextraction and UHPLC-MS/MS". Journal of Analytical Toxicology. 47 (9): 787–796. doi:10.1093/jat/bkad071. PMC 10714918. PMID 37700512.
- ^ Balcaen M, Ventura M, Gil C, Luf A, Martins D, Cunha M, et al. (March 2023). "Challenges in Drug Surveillance: Strengthening the Analysis of New Psychoactive Substances by Harmonizing Drug Checking Services in Proficiency Testing". International Journal of Environmental Research and Public Health. 20 (5): 4628. doi:10.3390/ijerph20054628. PMC 10002093. PMID 36901637.